AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31976548 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of TMP (100 mg, t.i.d. for 16 weeks) in a small cohort of patients with PAH or CTEPH
Number of subjects: 0
Study 30706426 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine U300
Number of subjects: 54
Study 30706426 — intervention group
Group type: COMPARATOR
Intervention: Insulin degludec U100
Number of subjects: 54
Study 28887192 — intervention group
Group type: EXPERIMENTAL
Intervention: eCoFit intervention (integrated group sessions and smartphone app)
Number of subjects: 84
Study 26029694 — intervention group
Group type: EXPERIMENTAL
Intervention: O-PAP (oscillating positive airway pressure)
Number of subjects: 14
Study 26029694 — intervention group
Group type: COMPARATOR
Intervention: CPAP (continuous positive airway pressure)
Number of subjects: 14
Study 26029694 — intervention group
Group type: EXPERIMENTAL
Intervention: O-PAP
Number of subjects: 14
Study 26029694 — intervention group
Group type: COMPARATOR
Intervention: CPAP
Number of subjects: 14
Study 22911223 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine plus epinephrine 100 μg
Number of subjects: 162
Study 22911223 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine plus epinephrine 200 μg
Number of subjects: 162
Study 22911223 — intervention group
Group type: COMPARATOR
Intervention: bupivacaine
Number of subjects: 162
Study 21564045 — intervention group
Group type: EXPERIMENTAL
Intervention: Airway Scope
Number of subjects: 140
Study 21564045 — intervention group
Group type: COMPARATOR
Intervention: Clarus Video System
Number of subjects: 140
Study 17991450 — intervention group
Group type: EXPERIMENTAL
Intervention: Intention formation
Number of subjects: 0
Study 16845866 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous access
Number of subjects: 99
Study 16845866 — intervention group
Group type: COMPARATOR
Intervention: Surgical cut-down
Number of subjects: 99
Study 15198841 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly fructosamine testing in addition to daily glucose monitoring (Group 1)
Number of subjects: 72
Study 15198841 — intervention group
Group type: COMPARATOR
Intervention: Usual care of daily glucose monitoring (Group 2)
Number of subjects: 72
Study 15198841 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly fructosamine testing (Group 1)
Number of subjects: 72
Study 15198841 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Group 2)
Number of subjects: 72
Study 11369660 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea (HU)
Number of subjects: 93
Study 9333659 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency capsulotomy
Number of subjects: 55
Study 9333659 — intervention group
Group type: COMPARATOR
Intervention: Capsulorhexis
Number of subjects: 55
Study 8282621 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 weeks of progressive bicycle training
Number of subjects: 18
Study 3567122 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg of salbutamol orally five times daily
Number of subjects: 200
Study 3567122 — intervention group
Group type: COMPARATOR
Intervention: No drug
Number of subjects: 200
Study 31062684 — intervention group
Group type: EXPERIMENTAL
Intervention: HIGH-Rasp (20% freeze-dried black raspberries)
Number of subjects: 20
Study 31062684 — intervention group
Group type: EXPERIMENTAL
Intervention: LOW-Rasp (10% freeze-dried black raspberries)
Number of subjects: 20
Study 31062684 — intervention group
Group type: COMPARATOR
Intervention: Reference (no fruit ingredients)
Number of subjects: 20
Study 31062684 — intervention group
Group type: EXPERIMENTAL
Intervention: LOW-Cran (0.5% cranberry extract)
Number of subjects: 20
Study 31062684 — intervention group
Group type: EXPERIMENTAL
Intervention: HIGH-Cran (1% cranberry extract)
Number of subjects: 20
Study 29797991 — intervention group
Group type: COMPARATOR
Intervention: Experimental group (CRSwNP)
Number of subjects: 41
Study 29797991 — intervention group
Group type: COMPARATOR
Intervention: Control group (CRSsNP)
Number of subjects: 41
Study 24818633 — intervention group
Group type: COMPARATOR
Intervention: COBRA therapy (methotrexate 7.5 mg/week, sulfasalazine 2 g/day, with initial prednisolone 60 mg/day)
Number of subjects: 162
Study 24818633 — intervention group
Group type: EXPERIMENTAL
Intervention: COBRA-light therapy (methotrexate increased to 25 mg/week with initial prednisolone 30 mg/day)
Number of subjects: 162
Study 24818633 — intervention group
Group type: EXPERIMENTAL
Intervention: Both COBRA and COBRA-light groups
Number of subjects: 162
Study 24818633 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 162
Study 24818633 — intervention group
Group type: COMPARATOR
Intervention: COBRA
Number of subjects: 162
Study 24818633 — intervention group
Group type: EXPERIMENTAL
Intervention: COBRA-light
Number of subjects: 162
Study 24818633 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept addition
Number of subjects: 162
Study 23278964 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive fractional bipolar radiofrequency (FRF) treatment
Number of subjects: 100
Study 21707852 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Number of subjects: 50
Study 21707852 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 18199590 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose drink (60 g in 500 ml)
Number of subjects: 15
Study 18199590 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose drink (60 g in 500 ml)
Number of subjects: 15
Study 18199590 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 15
Study 18199590 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose and Glucose drinks
Number of subjects: 15
Study 16442153 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 12‐9566 (tanomastat) 800 mg p.o. b.i.d.
Number of subjects: 243
Study 16442153 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 243
Study 16442153 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 12‐9566 (tanomastat)
Number of subjects: 243
Study 14615615 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation (5-10 day course of full-dose low-molecular-weight heparin followed by 3 months of lower-dose low-molecular-weight heparin)
Number of subjects: 0
Study 14615615 — intervention group
Group type: COMPARATOR
Intervention: Inferior vena cava filter placement
Number of subjects: 0
Study 11739865 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver paste (3.0, 7.5, or 15 mg vitamin A)
Number of subjects: 35
Study 11739865 — intervention group
Group type: COMPARATOR
Intervention: Vitamin A supplement (3.0, 7.5, or 15 mg vitamin A)
Number of subjects: 35
Study 9239992 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucine supplementation (50.0 +/- 3.3 mg/kg body weight per day)
Number of subjects: 20
Study 9239992 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 9239992 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucine supplementation
Number of subjects: 20
Study 8287270 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 19
Study 8287270 — intervention group
Group type: COMPARATOR
Intervention: Standing position
Number of subjects: 19
Study 3320807 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizine
Number of subjects: 12
Study 3320807 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31529084 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sugar enriched expressed breastmilk (EBM)
Number of subjects: 80
Study 31529084 — intervention group
Group type: COMPARATOR
Intervention: IV dextrose therapy (IVDx)
Number of subjects: 80
Study 31188728 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin plus finasteride
Number of subjects: 0
Study 31188728 — intervention group
Group type: COMPARATOR
Intervention: Doxazosin
Number of subjects: 0
Study 31188728 — intervention group
Group type: COMPARATOR
Intervention: Finasteride
Number of subjects: 0
Study 31188728 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (finasteride plus doxazosin)
Number of subjects: 0
Study 31188728 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29069152 — intervention group
Group type: EXPERIMENTAL
Intervention: GIC with 1.25% CHX
Number of subjects: 36
Study 29069152 — intervention group
Group type: EXPERIMENTAL
Intervention: GIC with 2.5% CHX
Number of subjects: 36
Study 29069152 — intervention group
Group type: COMPARATOR
Intervention: GIC
Number of subjects: 36
Study 26697853 — intervention group
Group type: EXPERIMENTAL
Intervention: Eight-session activity counselling program
Number of subjects: 80
Study 26697853 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard pulmonary rehabilitation)
Number of subjects: 80
Study 23248072 — intervention group
Group type: EXPERIMENTAL
Intervention: Opicapone 10 mg
Number of subjects: 64
Study 23248072 — intervention group
Group type: EXPERIMENTAL
Intervention: Opicapone 25 mg
Number of subjects: 64
Study 23248072 — intervention group
Group type: EXPERIMENTAL
Intervention: Opicapone 50 mg
Number of subjects: 64
Study 23248072 — intervention group
Group type: EXPERIMENTAL
Intervention: Opicapone 100 mg
Number of subjects: 64
Study 23248072 — intervention group
Group type: EXPERIMENTAL
Intervention: Opicapone 200 mg
Number of subjects: 64
Study 23248072 — intervention group
Group type: EXPERIMENTAL
Intervention: Opicapone 400 mg
Number of subjects: 64
Study 23248072 — intervention group
Group type: EXPERIMENTAL
Intervention: Opicapone 800 mg
Number of subjects: 64
Study 23248072 — intervention group
Group type: EXPERIMENTAL
Intervention: Opicapone 1200 mg
Number of subjects: 64
Study 23248072 — intervention group
Group type: EXPERIMENTAL
Intervention: Opicapone 50 mg with high-fat meal
Number of subjects: 64
Study 23248072 — intervention group
Group type: EXPERIMENTAL
Intervention: Opicapone 50 mg fasting
Number of subjects: 64
Study 23248072 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 21991569 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery with uncinectomy and middle meatal antrostomy
Number of subjects: 30
Study 21991569 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic sinus surgery with uncinectomy
Number of subjects: 30
Study 21991569 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery with middle meatal antrostomy
Number of subjects: 30
Study 21991569 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery (both techniques)
Number of subjects: 30
Study 18490378 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis with sulfamethoxazole/trimethoprim for 2 years
Number of subjects: 100
Study 18490378 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic prophylaxis
Number of subjects: 100
Study 18490378 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis with sulfamethoxazole/trimethoprim
Number of subjects: 100
Study 16567823 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine case management intervention
Number of subjects: 1665
Study 16567823 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1665
Study 12670781 — intervention group
Group type: EXPERIMENTAL
Intervention: cilomilast (15 mg)
Number of subjects: 21
Study 12670781 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 21
Study 12670781 — intervention group
Group type: EXPERIMENTAL
Intervention: cilomilast + salbutamol (400 microg)
Number of subjects: 21
Study 12670781 — intervention group
Group type: EXPERIMENTAL
Intervention: cilomilast + ipratropium bromide (80 microg)
Number of subjects: 21
Study 12670781 — intervention group
Group type: EXPERIMENTAL
Intervention: cilomilast + salbutamol + ipratropium
Number of subjects: 21
Study 11044163 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary resection
Number of subjects: 105
Study 11044163 — intervention group
Group type: COMPARATOR
Intervention: Secondary resection
Number of subjects: 105
Study 8776642 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Number of subjects: 60
Study 8776642 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-poor plasma (PPP)
Number of subjects: 60
Study 8776642 — intervention group
Group type: COMPARATOR
Intervention: Control group (no APP)
Number of subjects: 60
Study 1642114 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine (OXC) 600 mg
Number of subjects: 6
Study 1642114 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine (CBZ) 400 mg
Number of subjects: 6
Study 6299159 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid/antibiotic combination product (dexamethasone, neomycin, and polymyxin B) for three days prior to surgery and three weeks following surgery
Number of subjects: 23
Study 6299159 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 6299159 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid/antibiotic combination product
Number of subjects: 23
Study 30413879 — intervention group
Group type: EXPERIMENTAL
Intervention: QLB type 2 (QLB2)
Number of subjects: 5
Study 30413879 — intervention group
Group type: COMPARATOR
Intervention: QLBi
Number of subjects: 5
Study 27223684 — intervention group
Group type: EXPERIMENTAL
Intervention: Active PHR (HealthTrak) with personalized alerts
Number of subjects: 41
Study 27223684 — intervention group
Group type: COMPARATOR
Intervention: Passive PHR
Number of subjects: 41
Study 25615430 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (21 hr of in-service workshops plus 5 coaching sessions)
Number of subjects: 121
Study 25615430 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (workshops alone)
Number of subjects: 121
Study 24428097 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 136
Study 24428097 — intervention group
Group type: COMPARATOR
Intervention: Desflurane
Number of subjects: 136
Study 20980923 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotational vibration training (RVT), 12.5 Hz, 12 mm, three sessions per week, for 15 min
Number of subjects: 108
Study 20980923 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical vibration training (VVT), 35 Hz, 1.7 mm, three sessions per week, for 15 min
Number of subjects: 108
Study 20980923 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG), two blocks of 10 low-intensity gymnastics sessions
Number of subjects: 108
Study 20980923 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotational vibration training (RVT)
Number of subjects: 108
Study 20980923 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical vibration training (VVT)
Number of subjects: 108
Study 20980923 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 108
Study 19073783 — intervention group
Group type: EXPERIMENTAL
Intervention: Videotelephone support service in addition to the 24 hours 'on‐call' service
Number of subjects: 17
Study 17356258 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine 10 mg
Number of subjects: 309
Study 17356258 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 309
Study 15238902 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient beverage with a meal
Number of subjects: 40
Study 15238902 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient beverage without a meal
Number of subjects: 40
Study 11573667 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 5 mg ml(-1) in glucose 50 mg ml(-1)
Number of subjects: 40
Study 11573667 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine 5 mg ml(-1) in glucose 10 mg ml(-1)
Number of subjects: 40
Study 11573667 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 9553538 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramedullary hip screw
Number of subjects: 131
Study 9553538 — intervention group
Group type: COMPARATOR
Intervention: Sliding hip screw
Number of subjects: 131
Study 8955861 — intervention group
Group type: EXPERIMENTAL
Intervention: Test preparation of selegiline HCl (4 x 5 mg tablets)
Number of subjects: 25
Study 2387286 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurotol Slow (SR)
Number of subjects: 18
Study 2387286 — intervention group
Group type: COMPARATOR
Intervention: Tegretol (C)
Number of subjects: 18
Study 7013971 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy-chemotherapy (RT & CT)
Number of subjects: 23
Study 7013971 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (RT)
Number of subjects: 23
Study 30893358 — intervention group
Group type: EXPERIMENTAL
Intervention: Treated group (students enrolled in the new language course)
Number of subjects: 0
Study 30893358 — intervention group
Group type: COMPARATOR
Intervention: Non-treated group (students not enrolled in the new language course)
Number of subjects: 0
Study 28222742 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g HAM-RS2 muffins (n = 11)
Number of subjects: 18
Study 28222742 — intervention group
Group type: COMPARATOR
Intervention: 0 g HAM-RS2 muffins (control; n = 7)
Number of subjects: 18
Study 26808847 — intervention group
Group type: EXPERIMENTAL
Intervention: Unshod (barefoot) running at 85% of V[Combining Dot Above]O2max
Number of subjects: 14
Study 26808847 — intervention group
Group type: COMPARATOR
Intervention: Shod (wearing shoes) running at 85% of V[Combining Dot Above]O2max
Number of subjects: 14
Study 26808847 — intervention group
Group type: EXPERIMENTAL
Intervention: Unshod (barefoot) running at 65% and 75% of V[Combining Dot Above]O2max
Number of subjects: 14
Study 26808847 — intervention group
Group type: COMPARATOR
Intervention: Shod (wearing shoes) running at 65% and 75% of V[Combining Dot Above]O2max
Number of subjects: 14
Study 24289808 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride-free toothpaste containing 1.5% arginine
Number of subjects: 38
Study 24289808 — intervention group
Group type: COMPARATOR
Intervention: Regular fluoride-containing toothpaste
Number of subjects: 38
Study 22619083 — intervention group
Group type: EXPERIMENTAL
Intervention: Probable major depression (PHQ-assessed)
Number of subjects: 2053
Study 22619083 — intervention group
Group type: EXPERIMENTAL
Intervention: PHQ score of ≥ 10
Number of subjects: 2053
Study 22619083 — intervention group
Group type: EXPERIMENTAL
Intervention: Probable major depression (by PHQ-9)
Number of subjects: 2053
Study 22619083 — intervention group
Group type: COMPARATOR
Intervention: ACCORD primary composite outcome (cardiovascular death, nonfatal heart attack, or stroke)
Number of subjects: 2053
Study 22619083 — intervention group
Group type: COMPARATOR
Intervention: ACCORD microvascular composite outcome
Number of subjects: 2053
Study 19933407 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow-triggered adaptive servo-ventilation (ASV)
Number of subjects: 31
Study 19933407 — intervention group
Group type: COMPARATOR
Intervention: Continuous positive airway pressure (CPAP)
Number of subjects: 31
Study 18056821 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care
Number of subjects: 1801
Study 18056821 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1801
Study 16032784 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation (120 mg vitamin C, 30 mg vitamin E, 6 mg beta‐carotene, 100 microg selenium, and 20 mg zinc)
Number of subjects: 12741
Study 16032784 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation
Number of subjects: 12741
Study 16032784 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12741
Study 12170041 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural top-up with 10 ml ropivacaine, 0.75% (group 1, n = 10)
Number of subjects: 30
Study 12170041 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (group 2, n = 10)
Number of subjects: 30
Study 12170041 — intervention group
Group type: COMPARATOR
Intervention: No epidural top-up (group 3, n = 10)
Number of subjects: 30
Study 9627431 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive prenatal care at a multidisciplinary tertiary clinic
Number of subjects: 175
Study 9627431 — intervention group
Group type: COMPARATOR
Intervention: Prenatal care from a variety of area public health clinics
Number of subjects: 175
Study 8195979 — intervention group
Group type: EXPERIMENTAL
Intervention: HTR polymer bone replacement grafts
Number of subjects: 9
Study 8195979 — intervention group
Group type: COMPARATOR
Intervention: AOC bone replacement grafts
Number of subjects: 9
Study 2454361 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol 25 mg
Number of subjects: 12
Study 2454361 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol 50 mg
Number of subjects: 12
Study 2454361 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 28674740 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Intraligamentary Stabilization (DIS)
Number of subjects: 60
Study 28674740 — intervention group
Group type: COMPARATOR
Intervention: Primary ACL reconstruction (ACLR)
Number of subjects: 60
Study 27046472 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous platelet-rich fibrin (PRF) with resorbable collagen membrane
Number of subjects: 16
Study 27046472 — intervention group
Group type: COMPARATOR
Intervention: Guided tissue regeneration alone (control group)
Number of subjects: 16
Study 25525981 — intervention group
Group type: EXPERIMENTAL
Intervention: LG3, LTBP2, Cathepsin L
Number of subjects: 100
Study 25525981 — intervention group
Group type: EXPERIMENTAL
Intervention: NGAL, Cystatin C
Number of subjects: 100
Study 22460609 — intervention group
Group type: EXPERIMENTAL
Intervention: Lexical-semantic stimulation (LSS)
Number of subjects: 40
Study 22460609 — intervention group
Group type: COMPARATOR
Intervention: Unstructured cognitive stimulation (UCS)
Number of subjects: 40
Study 20420579 — intervention group
Group type: EXPERIMENTAL
Intervention: High-mono-unsaturated-fatty-acid (HMUFA) diet
Number of subjects: 0
Study 20420579 — intervention group
Group type: COMPARATOR
Intervention: High-saturated-fatty-acid (HSFA) diet
Number of subjects: 0
Study 20420579 — intervention group
Group type: COMPARATOR
Intervention: Low-fat/high-complex carbohydrate diet supplemented with 1.24 g/day of long-chain n-3 polyunsaturated fatty acid (LFHCC n-3)
Number of subjects: 0
Study 20420579 — intervention group
Group type: COMPARATOR
Intervention: Low-fat/high-complex carbohydrate diet with 1 g/day of sunflower oil high in oleic acid (LFHCC)
Number of subjects: 0
Study 18686769 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling/root planing plus test gel application (triclosan 1% + polydimethylsiloxane 13%)
Number of subjects: 20